10/23/2007 | SS | Bioenvision no longer traded as merger with Genzyme concludes
|
10/22/2007 | SS | Bioenvision shareholders say yes to Genzyme merger deal
|
10/10/2007 | SS | Bioenvision, Genzyme file petition, get court's OK for Oct. 22 special meeting
|
10/1/2007 | SS | SCO Capital to vote against Genzyme acquisition of Bioenvision, plans to nominate new board members
|
9/27/2007 | SS | Genzyme will not increase price for Bioenvision
|
9/12/2007 | SS | SCO reiterates plan for Bioenvision; not in favor of Genzyme merger
|
9/6/2007 | SS | Elliott Associates to vote against merger of Genzyme, Bioenvision
|
8/6/2007 | SS | Elliott Associates reports 5.8% ownership of Bioenvision
|
7/11/2007 | SS | Bioenvision shareholder offers plan to boost company's value after sale to Genzyme is rejected
|
7/10/2007 | SS | Genzyme completes tender offer for Bioenvision shares
|
7/3/2007 | SS | SCO calls on Bioenvision to abandon sale to Genzyme
|
7/2/2007 | SS | Genzyme extends tender for Bioenvision common, preferred stock
|
6/27/2007 | SS | Bioenvision shareholder reiterates disapproval of company's deal with Genzyme
|
6/5/2007 | SS | Bioenvision shareholders led by SCO Securities object to planned merger with Genzyme
|
5/30/2007 | SS | Market Commentary: Bioenvision climbs, Genzyme holds firms on deal opposition; Guitar Center gains further on sale hopes
|
5/29/2007 | SS | Genzyme's acquisition of Bioenvision builds on companies' oncology drug development
|
4/3/2007 | PP | Market Commentary: PolyMet stock gains 10% on $41.25 million private placement; ANTs raises $13 million
|
4/2/2007 | PP | New Issue: Bioenvision prices $30 million direct placement of stock
|
4/2/2007 | PP | Market Commentary: Enbridge seals $313.35 million PIPE; Eagle Rock Energy secures $127.5 million from units
|
11/9/2006 | BT | Bioenvision fiscal 1Q 2007 revenues surge higher, net loss at $12.2 million for period
|
10/27/2006 | BT | Market Commentary: Genzyme slides on deal buzz; Cadence, Achillion up; Aspreva falls; Vertex gains 18%; Critical off on PIPE
|
9/18/2006 | BT | Bioenvision expands into Japan, Southeast Asia
|
9/18/2006 | BT | Market Commentary: Genentech steady on Glaxo filing; Cell Therapeutics, Inovio gain on deals; MannKind up, Nektar down
|
9/11/2006 | BT | Bioenvision ends year with $3.4 million
|
9/8/2006 | BT | Bioenvision: Suvus decreases hepatitis C viral load up to 92%
|
7/19/2006 | BT | Market Commentary: Amgen up slightly ahead of earnings; Isis, NeoPharm, Genta up; Affymetrix off, Illumina up 29%
|
6/21/2006 | BT | Phase 2 study data shows Bioenvision's Evoltra as effective as chemotherapy in leukemia treatment
|
6/5/2006 | BT | Bioenvision study finds Evoltra helps survival in elderly AML patients with adverse cytogenetics
|
5/31/2006 | BT | Bioenvision receives European approval for Evoltra for acute lymphoblastic leukemia
|
4/5/2006 | BT | Bioenvision says Evoltra achieves high response rates in adult leukemia
|
8/31/2005 | BT | Bioenvision reiterated by Stanford at buy
|